New Study Demonstrates Advances in Creating Treatment for Common Childhood Blood Cancer

Researchers at NYU Langone Medical Center and elsewhere say that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. In a study led by senior investigator and cancer biologist Iannis Aifantis, PhD, published in the Oct. 23 edition of Nature, the NYULMC team concludes that the enzyme JMJD3 acts as a cancer “on” switch by splitting off a chemical methyl group of another protein that is usually methylated by a tumor-suppressing enzyme. Read more...


NYU Langone Medical Center to Spearhead Multi-Institutional MRSA Research Funded by the National Institutes of Health

Staphylococcus aureus (Sa) and methicillin-resistant staph aureus (MRSA) continue to be among the most common pathogens that overwhelm the immune system, causing serious skin, soft tissue and life-threatening blood-borne infections. Researchers at NYU Langone will lead a consortium of five institutions on a $6.5 million contract from the National Institutes of Health (NIH) directed at discovery of the fundamental immunology, microbial genetics, protein structure and proteomics of staphylococcus aureus. Read more...